Search results
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination. In a new review article, researchers from the International Agency for Research on Cancer (IARC) ... IARC hosts second annual meeting of DISCERN project. Researchers from the International Agency for Research on Cancer (IARC) are hosting the ...
Jun 29, 2023 · The sweetener aspartame, which is found in a variety of foods and fizzy drinks, is set to be officially classified as "possibly carcinogenic" to humans, reports claim. The label frequently causes ...
The International Agency for Research on Cancer (IARC) Monographs (www.monographs.iarc.fr) identify environmental and occupational causes of human cancer. Sometimes called the WHO “Encyclopedia of Carcinogens,” the IARC Monographs are critical reviews and evaluations of the weight of the evidence that an agent can increase the risk of ...
Dec 12, 2023 · IARC’s classification of PFOA in Group 1, “the agent is carcinogenic to humans,” is a definitive statement that PFOA causes cancer that runs counter to the findings of other scientists. As Dr. Dragani explained, Europe’s proposed ban on PFAS could impact 12,000 chemicals, and this issue could have a significant impact for years to come.
Jun 10, 2012 · IARC evaluations made of the carcinogenicity of trace elements and related compounds to humans by the international agency of research on cancer (IARC 1993) Group 1: carcinogenic to humans. Group 2A: probably carcinogenic. Group 2B: possibly carcinogenic. Group 3: not classifiable.
Feb 24, 2015 · The IARC Monographs on the Evaluation of Carcinogenic Risks to Humans of the International Agency for Research on Cancer (IARC) are a prominent example of such an expert review process. The goal of the Monograph Programme is to assess carcinogenic hazards from occupational, environmental, and lifestyle exposures and agents, thus providing an ...
Crotonaldehyde and arecoline were classified as possibly carcinogenic to humans (Group 2B) on the basis of strong mechanistic evidence. The outcome of the assessment has been published in a summary article in The Lancet Oncology 1 and will be described in detail in Volume 128 of the IARC Monographs , to be published in 2021.
